Vaccination of the stem cell transplant recipient and the hematologic malignancy patient

M Kamboj, MK Shah - Infectious Disease Clinics, 2019 - id.theclinics.com
Due to advances in cancer treatment and earlier cancer detection, coupled with the aging
and overall growth of the population, the number of cancer survivors in the United States is …

Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen.(III) Impfen bei hämatologischen und …

HJ Laws, U Baumann, C Bogdan, G Burchard… - 2020 - Springer
In Deutschland leben aktuell circa 4 Mio. Menschen, die in ihrem Leben eine
Krebserkrankung diagnostiziert bekommen haben [171]. Im Zeitraum von 1980–2017 …

Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host …

MC Zanella, S Cordey, F Laubscher, M Docquier… - Microbiome, 2021 - Springer
Background Viral infections are common complications following allogeneic hematopoietic
stem cell transplantation (allo-HSCT). Allo-HSCT recipients with steroid …

Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation

M McMasters, BM Blair, HM Lazarus, CD Alonso - Blood Reviews, 2021 - Elsevier
Patients who have hematologic malignancies are at high risk for infections but vaccinations
may be effective prophylaxis. The increased infection risk derives from immune defects …

Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT

G Punchhi, R Negus, H Saif, S Pritchard, O Owen… - Vaccine, 2023 - Elsevier
Measles outbreaks have raised concerns of fatal infections in immunocompromised patients.
Canadian guidelines advise administration of live vaccines, such as measles, mumps, and …

Immunity and vaccination against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplant recipients

K Kawamura, H Wada, H Nakasone, Y Akahoshi… - … and Cellular Therapy, 2021 - Elsevier
Large outbreaks of measles or rubella occasionally occur around the world, and measles
infection can be severe and even fatal in transplant patients. However, limited data are …

Safety of live-attenuated measles, mumps, and rubella vaccine administered within 2 years of hematopoietic cell transplant

M Desjardins, X Mitre, AC Sherman… - Open Forum …, 2021 - academic.oup.com
Background Measles, mumps, and rubella (MMR) vaccine is a live-attenuated vaccine
usually contraindicated within the first 2 years of hematopoietic cell transplant (HCT). The …

[HTML][HTML] Safety and seropositivity after live attenuated vaccine in adult patients receiving hematopoietic stem cell transplantation

T Aoki, T Kamimura, S Yoshida, Y Mori… - Biology of Blood and …, 2019 - Elsevier
Vaccination against vaccine-preventable diseases (VPDs) is highly recommended for
hematopoietic stem cell transplantation (HSCT) recipients by several guidelines; however …

Long-Term Immunity to Measles after Allogeneic Hematopoietic Cell Transplantation: Factors Associated with Seroprotection before Revaccination

C Robin, AA Mariaggi, R Redjoul, M Leclerc… - Biology of Blood and …, 2020 - Elsevier
Measles can be a life-threatening infection in immunocompromised patients, especially after
allogeneic hematopoietic cell transplantation (HCT) because of the corresponding loss of …

Vacunación de pacientes adultos receptores de trasplante de células madre hematopoyéticas: Perspectiva de Costa Rica

M Espínoza Mora, G Lazo Páez… - Revista chilena de …, 2016 - SciELO Chile
El presente artículo revisa las recomendaciones actuales para la inmunización de pacientes
adultos que han recibido trasplante de células madre hematopoyéticas, procedimiento …